<DOC>
	<DOC>NCT00310596</DOC>
	<brief_summary>The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine) injection has on the way the heart conducts the electrical impulses that allow it to beat effectively. The study will compare Magnevist injection's effect to that of placebo (a saline injection).</brief_summary>
	<brief_title>Cardiovascular Safety Study of MagnevistÂ® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Subjects with an electrocardiogram [ECG] (normal sinus rhythm [SR], QTc &gt; 450 msec) without clinically significant abnormalities Nonsmoker History of cardiovascular disease Pregnant or nursing Had any contraindication to moxifloxacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ECG safety</keyword>
</DOC>